Cerus (NASDAQ:CERS) Posts Quarterly Earnings Results, Hits Estimates

Cerus (NASDAQ:CERS) posted its earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01), Zacks reports. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%.

Cerus Price Performance

NASDAQ:CERS opened at $1.74 on Friday. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The company has a 50 day moving average price of $1.74 and a 200-day moving average price of $1.84. Cerus has a 1-year low of $1.38 and a 1-year high of $2.59.

Insider Activity

In related news, Director Eric Bjerkholt sold 20,000 shares of Cerus stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $1.78, for a total value of $35,600.00. Following the sale, the director now owns 162,133 shares of the company’s stock, valued at approximately $288,596.74. This trade represents a 10.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.40% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.